Nystatin
Brand names: Klayesta, Nystatin, Nystop, Nyamyc
At a glance
- Medicare prescriptions, 2024
- 2,123,898
- Medicare drug cost
- $42.5M
- Average cost per prescription
- $20.03
- Clinicians who prescribed it
- 79,281
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
From the FDA-approved prescribing information (label dated October 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 28.2%
- Nurse Practitioners 25.8%
- Internal Medicine 22.5%
- Physician Assistants 7.7%
- Dermatology 3.3%
- Geriatric Medicine 2.5%
- Podiatrists 2.1%
- OB-GYN (Obstetrics & Gynecology) 1.1%
- General Practice 1.0%
- Pulmonology 0.6%
- Hospitalist 0.5%
- ENT (Otolaryngology) 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 12% from 2019 to 2024.
Biggest change by state since 2019
- Nevada +24%
- Rhode Island +23%
- South Carolina +23%
- Maryland +22%
- Utah +22%
- Puerto Rico (smallest change) −10%
- Nebraska (smallest change) −2%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100000 [USP'U] | yellow suspension | |
Preferred Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100000 [USP'U] | yellow suspension | |
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 100000 [USP'U] | yellow cream | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
5 recalls since 2020
- Jun 2026 · Padagis US LLC · Class II
Subpotent Drug: Low out of specification assay results performed during long-term stability testing. - Jul 2021 · Pai Holdings, LLC. dba Pharmaceutical Associates Inc · Class II
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup. - Aug 2020 · Pai Holdings, LLC. dba Pharmaceutical Associates Inc · Class II
Subpotent drug: Out of specification for assay at the 15-month test interval. - Mar 2020 · Pai Holdings, LLC. dba Pharmaceutical Associates Inc · Class II
SubPotent Drug: Low out-of-specification results for assay testing. - Jan 2020 · Pharmaceutical Associates Inc · Class II
Subpotent: Out of specification for assay at the 12-month time point.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.